Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice.

ABSTRACT:

Background

Lung cancer is a leading cause of cancer-related death in Germany and worldwide. Non-small cell lung cancer (NSCLC) comprises ~80% of lung cancer diagnoses; in White patients, around 10% of NSCLC cases are epidermal growth factor receptor mutation-positive (EGFRm+). Head-to-head clinical trials have demonstrated superior efficacy with second-/third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) versus first-generation EGFR TKIs in EGFRm+ NSCLC. Data from routine clinical practice are necessary to confirm that clinical trial findings are transferable to real-world populations.

Methods

In NCT02047903, a prospective non-interventional study in Germany, patients with EGFRm+ NSCLC received first-line afa

SUBMITTER: Bruckl WM 

PROVIDER: S-EPMC8111535 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature